This new treatment option can redefine how we approach RRMM treatment by giving healthcare providers a regimen with improvement in PFS and OS and a well-characterized safety profile
The company announced positive topline data from the Phase II ZUPREME-1 trial
Evogene said ChemPass AI was significantly expanded during 2025 through internal development and collaborations with Google Cloud
Hyderabad emerged as Lonza’s preferred destination after an extensive global evaluation process
Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results
ShunzymeX leverages a proprietary protease to streamline purification
The system also introduces Imaging Scanner Interface 2 (ISI2) capability, enabling direct communication between injector and scanner to improve exam coordination and operational efficiency
Designed for intense clinical environments, Rembra can handle up to 270 exams per day
Subscribe To Our Newsletter & Stay Updated